Our Expertise
Lumiphore is a radiopharmaceutical company leveraging novel macrocyclic BiFunctional Chelate (mBFC) technology into diagnostic and therapeutic constructs to improve human health. With deep domain knowledge regarding metals in medicine, Lumiphore is applying decades of chelation expertise to both existing and novel cancer targeting agents to create best-in-class medicines. These novel constructs allow for rapid, room temperature chelation of a wide range of promising radioisotopes, with high in-vivo stability covering imaging and therapeutics with a single compound matched with multiple radionuclides.
Single Molecule Targeted Radiotheranostics
Lumiphore has leveraged proprietary chelation technology into multiple projects internally and with partners to bring next-generation radiopharmaceuticals into the clinic. We are actively seeking partners with novel targeting agents for additional programs…
Learn More...
Enabling TRT Platform Technonolgy
A novel and proprietary platform technology for metal chelation has provided the foundation for next-generation radiopharmaceuticals. By combining optimized scaffolds and bidentate chelation structures, preorganized macrocyclic BiFunctional Chelates (mBFC) are produced, optimized for radiothernostic applications…
Learn More...
Next Generation Chelation Technology
Lumiphore chelates meet fundamental principles of high in-vivo stability, simple labeling of targeting agents, easy radionuclide incorporation at temperatures below 37C to maintain targeting agent fidelity, high versatility to bind different metals with the same chelate.
Learn More...
Sensitive Mix-and-Read Diagnostics
Lumiphore’s proprietary compounds also sensitize Eu and Tb with best-in-class brightness based on unparalleled quantum yields and high coefficients of extinction. These long fluorescent lifetime compounds are well suited for Mix-N-Read diagnostics and High Content Screening (HCS) drug discovery programs need the highest sensitivity and stability...
Learn More...
